Established in 2018, the Pharmaceutical Open Source Software Consortium (POSSC) is focused on the development of innovative open-source solutions (open source based software) for pharmacokinetic or pharmacometric applications to serve the Clinical Pharmacology and Pharmacometric Community, standardize common elements, strengthen the discipline, and ultimately bring new medicines to patients. 


The POSSC effort has been divided into two phases:

  1. Feasibility Phase - consists of the formation of the consortium, definition of NCA software requirements, and public solicitation for interest and information to deliver the NCA solution.  All of the information learned during the Feasibility Phase will support the business case used by POSSC members to make the decision to enter the next project phase.  The Feasibility phase currently in progress and is scheduled to be completed in October 2018.

  2. Development Phase - comprised of selecting a vendor to deliver the NCA software, finalization of requirements, and kick-off of development. The Development Phase will commence once a decision to proceed has been reached by the POSSC members and will continue until the NCA software is delivered.​


Membership within POSSC is currently open to any company engaged in the development of new chemical entities or new molecular entities for the prevention, diagnosis, or treatment of disease with at least one active clinical trial application.  POSSC is comprised of the following Pharmaceutical and Biotechnology companies:

  • Amgen

  • AstraZeneca

  • Biogen

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Eli Lilly

  • Genentech

  • GlaxoSmithKline

  • Johnson & Johnson

  • Pfizer

  • Takeda Pharmaceuticals

Any companies interested in membership in POSSC are invited to contact the POSSC Secretariat, Drinker Biddle & Reath, LLP​.


Request for Information

POSSC has published a Request for Information (RFI) to solicit interest in collaborating together on a Next Generation Non-Compartmental Analysis (NCA) Platform.  The information collected during the RFI process along with subsequent interviews and follow-up interactions will be used for evaluation purposes, to provide information to support the creation of the business case to enter the Development Phase, and selection of respondent(s) who may be invited to respond to a future Request for Proposals (RFP).

Anticipated Time Frames for Evaluation and Selection Process (subject to change):

  • RFI Released: May 29, 2018

  • Informational Webinar #1: June 22, 2018 (12:30 - 2:00 PM EDT) - (download slides)

  • Informational Webinar #2: July 17, 2018  (1:00 - 2:30 PM EDT)

  • Responses to RFI due: July 30, 2018

  • Evaluation of Responses: July 30 - August 10, 2018

  • Notification of Status/Interview Invitations: August 10, 2018

  • In-Person Interviews (Secretariat Offices, New York City): August 21 and 22, 2018 (by invitation)

Contact Us

We want to hear from you!

Tel: 202.230.5661

Faegre Drinker Biddle and Reath,LLP
1500 K Street NW; Washington DC 20005


Thanks! Message sent.